Liver cancer drug safety checked in 263 patients
NCT ID NCT05100082
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at side effects of the drug Cabometyx in 263 Japanese adults with advanced liver cancer that had worsened after other treatments. Doctors monitored participants for 12 months to record any serious or severe side effects. The goal was to understand the drug's safety, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Takeda Selected Site
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Gut bacteria transplant may supercharge liver cancer immunotherapy
- Engineered immune cells take on liver cancer in early trial
- New drug MDX2001 tested in 285 patients with advanced cancers
- Can a simple blood test predict cancer return? new study investigates
- Blow into this tube: a simple breath test might spot liver disease early